(Q41729315)

English

Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions

scientific article published on January 1998

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

8 October 2017

1 reference

Europe PubMed Central

Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions (English)

1 reference

Europe PubMed Central

8 October 2017

1 reference

based on heuristic

inferred from title

author name string

Beach JW

1

1 reference

Europe PubMed Central

8 October 2017

publication date

1 January 1998

1 reference

Europe PubMed Central

8 October 2017

Clinical Therapeutics

1 reference

Europe PubMed Central

8 October 2017

20

1 reference

Europe PubMed Central

8 October 2017

2-25; discussion l

1 reference

Europe PubMed Central

8 October 2017

1

1 reference

Europe PubMed Central

8 October 2017

Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics of oral zidovudine (azidothymidine) in patients with AIDS when administered with and without a high-fat meal

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Fetoplacental passage of zidovudine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of various drugs on the glucuronidation of zidovudine (azidothymidine; AZT) by human liver microsomes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Zidovudine-induced hepatotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Nail dyschromia associated with zidovudine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Antibacterial activity and mechanism of action of 3'-azido-3'-deoxythymidine (BW A509U)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of replication and cytopathic effect of human T cell lymphotropic virus type III/lymphadenopathy-associated virus by 3'-azido-3'-deoxythymidine in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of (-)-2'-deoxy-3'-thiacytidine (3TC) 5'-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Cellular metabolism of (−) enantiomeric 2′-deoxy-3′-thiacytidine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Fatal pancreatitis as a complication of therapy for HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. II. The effects of different oral formulations and the presence of other medications.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of time of food administration on the bioavailability of didanosine from a chewable tablet formulation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS and related disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacodynamics of 2′,3′-dideoxycytidine: An inhibitor of human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-dose zalcitabine-related toxic neuropathy: frequency, natural history, and risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Initial studies on the cellular pharmacology of 2',3-dideoxycytidine, an inhibitor of HTLV-III infectivity.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Cellular pharmacology of 2',3'-dideoxy-2',3'-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative studies of 2',3'-didehydro-2',3'-dideoxythymidine (D4T) with other pyrimidine nucleoside analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of in vitro biological properties and mouse toxicities of three thymidine analogs active against human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics of nevirapine: initial single-rising-dose study in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonnucleoside inhibitors of HIV-1 reverse transcriptase: nevirapine as a prototype drug

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Steady state kinetics and inhibition of HIV-1 reverse transcriptase by a non-nucleoside dipyridodiazepinone, BI-RG-587, using a heteropolymeric template

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

HIV drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro protein-binding characteristics of delavirdine and its N-dealkylated metabolite

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Simple, rapid and sensitive high-performance liquid chromatographic determination of delavirdine and its N-desisopropyl metabolite in human plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiviral activity of human immunodeficiency virus type 1 protease inhibitors in a single cycle of infection: evidence for a role of protease in the early phase

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2',3'-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and activity of saquinavir in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Current knowledge and future prospects for the use of HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Regiospecific intestinal absorption of the HIV protease inhibitor L-735,524 in beagle dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Protein structure-based design of potent orally bioavailable, nonpeptide inhibitors of human immunodeficiency virus protease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980031-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0149-2918(98)80031-3

1 reference

Europe PubMed Central

8 October 2017

1 reference

Europe PubMed Central

8 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41729315&oldid=1926638170"